Lipocine Stock Jumps On Litigation Settlement With Clarus Therapeutics

by Vandana Singh, Benzinga Editor

July 15, 2021 6:03 AM | 1 min read | Make a Comment

Lipocine Inc LPCN has entered into a settlement and license agreement with Clarus Therapeutics to resolve claims in the ongoing intellectual property litigation and interference proceeding.
Under the terms of the settlement, both the companies have agreed to dismiss the litigation presently pending in the District Court for the District of Delaware.
Additionally, both parties have agreed on the interference proceedings presently pending in the U.S. Patent and Trademark.
The terms of the settlement remain confidential.
Price Action: LPCN shares are up 6.98% at $1.38 during the premarket session on the last check Thursday.

Posted In: Biotech News Penny Stocks Health Care Legal General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.